Last reviewed · How we verify
Parabolan (trenbolone hexahydrobenzylcarbonate)
Parabolan (generic name: trenbolone hexahydrobenzylcarbonate) is a drug. It is currently in unknown development.
Parabolan works by binding to androgen receptors in the body, mimicking the effects of testosterone and promoting muscle growth and development.
Parabolan is a synthetic, injected anabolic-androgenic steroid (AAS) of the nandrolone group, specifically the C17β hexahydrobenzylcarbonate ester of trenbolone. It is a small molecule modality, classified under the brand names Parabolan and Hexabolan.
At a glance
| Generic name | trenbolone hexahydrobenzylcarbonate |
|---|---|
| Target | Polymerase acidic protein, Androgen receptor |
| Therapeutic area | Other |
| Phase | unknown |
Mechanism of action
Imagine your body's cells have locks on them, and the key to unlocking muscle growth is a hormone called testosterone. Parabolan is a synthetic key that fits into these locks, allowing it to stimulate muscle growth and development. This process can lead to increased muscle mass and strength, but it can also have negative effects on the body if used improperly.
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Parabolan CI brief — competitive landscape report
- Parabolan updates RSS · CI watch RSS
- portfolio CI
Frequently asked questions about Parabolan
What is Parabolan?
How does Parabolan work?
What is the generic name of Parabolan?
What development phase is Parabolan in?
What does Parabolan target?
Related
- Target: All drugs targeting Polymerase acidic protein, Androgen receptor
- Manufacturer: — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing